Charles Moore, MD
Internal Medicine · Catonsville, MDNPI 1275687493
Payments from drug & device makers
Across 297 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AstraZeneca$1K
- Sanofi-aventis U.S. LLC$884
- Novo Nordisk$800
- Johnson & Johnson$481
- AbbVie$432
- plus $2K from 20 others
What the payments were for
- Consulting fees$1,24118%
- Food & beverage$5,78982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $1,432 |
| AstraZeneca | 57 | $1,245 |
| Sanofi-aventis U.S. LLC | 43 | $884 |
| Novo Nordisk | 42 | $800 |
| Johnson & Johnson | 29 | $481 |
| AbbVie(2 entities) | 25 | $432 |
| Lilly USA, LLC | 17 | $318 |
| Amgen(2 entities) | 12 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $233 |
| Arbor Pharmaceuticals, Inc. | 10 | $145 |
| Boehringer Ingelheim | 7 | $145 |
| Pfizer | 8 | $138 |
| Xeris Pharmaceuticals, Inc. | 4 | $91 |
| Merck | 6 | $79 |
| Ultragenyx Pharmaceutical Inc. | 3 | $75 |
| GSK | 3 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Abbott | 1 | $29 |
| Exact Sciences | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Medtronic | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$1,354
How this compares
$7,030 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 69 | $66,875 |
| RybelsusSemaglutide | 26 | $57,572 |
| MounjaroTirzepatide | 41 | $57,287 |
| EliquisApixaban | 26 | $33,923 |
| JardianceEmpagliflozin | 32 | $29,544 |
| TrulicityDulaglutide | 19 | $29,358 |
| XareltoRivaroxaban | 18 | $24,330 |
| JanuviaSitagliptin Phosphate | 13 | $17,018 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,275 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 18 | $12,213 |
| OzempicSemaglutide | 11 | $12,088 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $11,809 |
| Dexlansoprazole DrDexlansoprazole | 35 | $11,454 |
| TrintellixVortioxetine Hydrobromide | 18 | $11,045 |
| MyrbetriqMirabegron | 18 | $10,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $318 | $86,64560 claims |
| Novo NordiskRybelsus, Ozempic | $800 | $69,66037 claims |
| AstraZenecaFarxiga | $1,245 | $66,87569 claims |
| PfizerEliquis | $138 | $33,92326 claims |
| Boehringer IngelheimJardiance | $145 | $29,54432 claims |
| MerckJanuvia, Janumet | $79 | $26,87528 claims |
| Johnson & JohnsonXarelto | $481 | $24,33018 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $56 | $19,72832 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $145 | $12,21318 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $884 | $11,80912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $233 | $11,04518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Catonsville
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.